Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Biotech
Amgen posts ph. 3 Sjögren’s data ahead of Novartis showdown
Amgen shared data from a phase 3 Sjögren’s disease trial that dazzled analysts, digging into the details that could shape its showdown with Novartis.
Nick Paul Taylor
Nov 11, 2026 8:00am
AHA: Novartis’ Lp(a) drug shows zero benefit
Nov 7, 2026 9:50am
Novo saying goodbye to longtime finance chief—Chutes & Ladders
Nov 6, 2026 10:12am
Roche pays Zymeworks $55M for challenger to Amgen’s Imdelltra
Oct 23, 2026 7:28am
Amgen reveals 6-point drop in lupus severity behind ph. 2 win
Sep 30, 2026 4:26am
Amgen fusion protein eases Sjögren's severity in ph. 3 win
Sep 22, 2026 10:20am